ARCTIC BIOSCIENCE NK -10 risk profile
67 Stretched several inputs deteriorating together
Measured 1 September 2026 from 9TD's filed statements. Recomputed nightly.
67 (Stretched), driven by Cash conversion at 100, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 67 | Stretched | Stable | Drawdown from the 52-week high — 37.5% |
| Operating pressure | 2 | Contained | Stable | Costs outgrowing revenue — -11.6 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -1.00x |
| Leverage and coverage | 99 | Acute | Stable | Net debt to EBITDA |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for ARCTIC BIOSCIENCE NK -10